In Silico Drug Discovery Market Outlook 2026-2030: Investment Trends, Strategic Profiles and Revenue Share Outlook
Dublin, Sept. 17, 2026 (GLOBE NEWSWIRE) -- "In Silico Drug Discovery Market Report 2026" has been added to ResearchAndMarkets.com's offering.
In Silico Drug Discovery Market to Reach $7.42 Billion by 2030 as AI Adoption Accelerates
The global in silico drug discovery market is experiencing rapid expansion as pharmaceutical and biotechnology organizations adopt artificial intelligence, molecular modeling, virtual screening and predictive analytics to improve drug development. The market is projected to grow from $4.21 billion in 2025 to $4.71 billion in 2026, representing a compound annual growth rate (CAGR) of 11.8%.
Historical market growth has been supported by rising pharmaceutical research and development costs, the early adoption of molecular modeling tools, advances in computational chemistry, expanding genomic databases and stronger collaboration between academic institutions and industry participants. These factors have increased demand for technologies that help researchers identify viable drug candidates, evaluate potential risks and optimize compounds before moving into resource-intensive laboratory and clinical development.
The in silico drug discovery market is forecast to reach $7.42 billion by 2030, expanding at a CAGR of 12.1%. Growth during the forecast period is expected to be driven by demand for faster drug development cycles, increasing use of machine learning in pharmacology, wider adoption of cloud computing across the life sciences sector and a stronger focus on precision medicine. The growing use of simulated clinical trials is also expected to support market expansion.
Key in silico drug discovery market trends include the increasing implementation of AI-powered virtual screening platforms, cloud-based drug discovery software, predictive toxicology models and advanced target identification and validation tools. Data-driven lead optimization is becoming particularly important as drug developers seek to improve candidate selection, reduce late-stage failures and allocate research funding more efficiently.
Rising pharmaceutical R&D investment is a major growth driver. Drug developers are increasing spending to address complex, chronic and underserved diseases with more targeted therapies. In silico platforms help organizations screen and optimize candidates more quickly, enabling researchers to prioritize compounds with the strongest potential and improve returns on development expenditure. In April 2025, the UK Office for National Statistics reported that the UK government's net R&D spending increased by 8.2%, rising from $20.45 billion (£16.1 billion) in 2022 to $22.1 billion (£17.4 billion) in 2023.
Market participants are also investing in pharmaceutical-grade AI benchmarking and training platforms designed to improve the accuracy, reliability and predictive performance of computational drug discovery. In January 2026, Insilico Medicine launched Science MMAI Gym, a specialized platform for enhancing large language models used in chemistry, biology and clinical research. The platform applies multi-task fine-tuning and reinforcement learning to support applications such as retrosynthesis, target assessment and clinical trial prediction, while offering access to laboratory validation capabilities.
Strategic consolidation is further reshaping the competitive environment. In November 2024, Recursion Pharmaceuticals acquired Exscientia for an undisclosed amount. The transaction combines Exscientia's precision chemistry design and automated small-molecule synthesis capabilities with Recursion's technology-enabled discovery platform. The integrated approach is intended to accelerate drug discovery and strengthen partnerships across oncology and other therapeutic areas.
Tariffs are influencing the in silico drug discovery market by raising the cost of imported high-performance computing hardware, data storage systems, specialized software licenses and advanced semiconductor components. Pharmaceutical and biotechnology companies in North America and Europe are particularly affected because of their reliance on global technology suppliers, while organizations in Asia-Pacific face higher costs for cloud infrastructure and computational services. Although these pressures may delay platform upgrades and increase operating expenses, they are also encouraging regional software development, investment in local cloud infrastructure and greater adoption of cost-efficient digital drug discovery solutions.
Markets Covered:
1) By Component: Software; Services
2) By Deployment: On-Premise; Cloud-Based Source
3) By Drug-Discovery Phase: Target Identification and Validation; Hit Identification; Lead Optimization; Candidate Validation
4) By Therapeutic Area: Oncology; Neurology; Cardiovascular; Infectious Diseases; Metabolic Disorders
5) By End User: Pharmaceutical Companies; Biotechnology Firms; Academic and Research Institutes; Contract Research Organization
Subsegments:
1) By Software: Molecular Modeling and Simulation; Pharmacophore Modeling Software; Virtual Screening Tools; Quantitative Structure Activity Relationship Modeling; Protein Structure Prediction Software; Ligand Based Design Software; De Novo Drug Design Software; Cheminformatics and Data Analysis Tools
2) By Services: Algorithm Development Services; Model Customization and Tailoring Services; Data Analytics Consulting Services; Computational Screening and Outsourcing Services; Protein Modeling and Simulation Services; Virtual Library Design Services; Target Assessment and Validation Services; Lead Optimization and Candidate Evaluation Services
Time Series:
Five years historic and ten years forecast.
Data:
Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation:
Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
Companies Featured
The companies featured in this In Silico Drug Discovery market report include:
For more information about this report visit https://www.researchandmarkets.com/r/yuid1t
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.